328 related articles for article (PubMed ID: 26458859)
1. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2.
Wen L; Cheng F; Zhou Y; Yin C
Saudi J Gastroenterol; 2015; 21(5):313-9. PubMed ID: 26458859
[TBL] [Abstract][Full Text] [Related]
2. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
3. miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2.
Bao J; Xu Y; Wang Q; Zhang J; Li Z; Li D; Li J
Biomed Pharmacother; 2017 Aug; 92():1030-1037. PubMed ID: 28609840
[TBL] [Abstract][Full Text] [Related]
4. Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2.
Wang H; Zhang X; Liu Y; Ni Z; Lin Y; Duan Z; Shi Y; Wang G; Li F
Oncotarget; 2016 Jun; 7(24):36577-36589. PubMed ID: 27174918
[TBL] [Abstract][Full Text] [Related]
5. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
Cao W; Yang W; Fan R; Li H; Jiang J; Geng M; Jin Y; Wu Y
Tumour Biol; 2014 Feb; 35(2):1287-95. PubMed ID: 24068565
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
7. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp.
Lu C; Shan Z; Li C; Yang L
Biomed Pharmacother; 2017 Feb; 86():450-456. PubMed ID: 28012924
[TBL] [Abstract][Full Text] [Related]
8. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
9. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
10. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
11. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET.
Zhang Z; Kong Y; Yang W; Ma F; Zhang Y; Ji S; Ma EM; Liu H; Chen Y; Hua Y
Oncol Rep; 2016 Oct; 36(4):2391-7. PubMed ID: 27513895
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
Zheng H; Wang JJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
[TBL] [Abstract][Full Text] [Related]
15. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway.
Zhou C; Chen L; Chen R; Xu F; Huang Z; Huang R; Wang W; Xu Q
J Chemother; 2022 Feb; 34(1):35-44. PubMed ID: 34167436
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.
Gong Y; Ren J; Liu K; Tang LM
World J Gastroenterol; 2015 Mar; 21(10):2949-58. PubMed ID: 25780292
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells.
Jiang T; Dong P; Li L; Ma X; Xu P; Zhu H; Wang Y; Yang B; Liu K; Liu J; Xue J; Lv R; Su P; Kong G; Chang Y; Zhao C; Wang L
Oncol Rep; 2017 Jul; 38(1):151-158. PubMed ID: 28534959
[TBL] [Abstract][Full Text] [Related]
18. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
19. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
20. Targeted Regulation of FoxO3a by miR-372 to Mediate Gastric Carcinoma Cell Apoptosis and DDP Drug Resistance.
Wang C; Wang C; Qiu C; Su Z
Cancer Biother Radiopharm; 2020 Dec; 35(10):753-759. PubMed ID: 32379491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
